Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase II Study of Talimogene Laherparepvec (T-VEC) Administered Concurrently With the Anti-PD1 Monoclonal Antibody Pembrolizumab in Patients With Metastatic and/or Locally Advanced Sarcoma

Next Previous
X
Search
Trial Profile

A Phase II Study of Talimogene Laherparepvec (T-VEC) Administered Concurrently With the Anti-PD1 Monoclonal Antibody Pembrolizumab in Patients With Metastatic and/or Locally Advanced Sarcoma

Status: Active, no longer recruiting
Phase of Trial: Phase II

Latest Information Update: 01 Aug 2024

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Pembrolizumab (Primary) ; Talimogene laherparepvec (Primary)
  • Indications Haemangiosarcoma; Malignant fibrous histiocytoma; Sarcoma
  • Focus Therapeutic Use

    • Most Recent Events

    • 20 Nov 2023 Planned End Date changed from 1 Mar 2024 to 1 Mar 2025.
    • 20 Nov 2023 Planned primary completion date changed from 1 Mar 2024 to 1 Mar 2025.
    • 06 Jun 2023 Efficacy results in three histology specific expansion cohorts: 1) UPS/MFS, 2) cutaneous AS and 3) ES presented at the 59th Annual Meeting of the American Society of Clinical Oncology.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top